These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28427690)

  • 1. Factors associated with adherence to disease modifying therapy in multiple sclerosis: An observational survey from a referral center in Lithuania.
    Duchovskiene N; Mickeviciene D; Jurkeviciene G; Dirziuviene B; Balnyte R
    Mult Scler Relat Disord; 2017 Apr; 13():107-111. PubMed ID: 28427690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence and persistence to drug therapies for multiple sclerosis: A population-based study.
    Evans C; Marrie RA; Zhu F; Leung S; Lu X; Melesse DY; Kingwell E; Zhao Y; Tremlett H
    Mult Scler Relat Disord; 2016 Jul; 8():78-85. PubMed ID: 27456879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study).
    Jongen PJ; Lemmens WA; Hoogervorst EL; Donders R
    Health Qual Life Outcomes; 2017 Mar; 15(1):50. PubMed ID: 28292329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study.
    Hansen K; Schüssel K; Kieble M; Werning J; Schulz M; Friis R; Pöhlau D; Schmitz N; Kugler J
    PLoS One; 2015; 10(7):e0133279. PubMed ID: 26214805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low.
    Wong J; Gomes T; Mamdani M; Manno M; O'Connor PW
    Can J Neurol Sci; 2011 May; 38(3):429-33. PubMed ID: 21515501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
    Calkwood J; Cree B; Crayton H; Kantor D; Steingo B; Barbato L; Hashmonay R; Agashivala N; McCague K; Tenenbaum N; Edwards K
    BMC Neurol; 2014 Nov; 14():220. PubMed ID: 25424122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.
    McKay KA; Tremlett H; Patten SB; Fisk JD; Evans C; Fiest K; Campbell T; Marrie RA;
    Mult Scler; 2017 Apr; 23(4):588-596. PubMed ID: 27357507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Affecting the Adherence to Disease-Modifying Therapy in Patients With Multiple Sclerosis.
    Erbay Ö; Usta Yeşilbalkan Ö; Yüceyar N
    J Neurosci Nurs; 2018 Oct; 50(5):291-297. PubMed ID: 30138155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of betaplus program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicentric cross-sectional survey in the western Balkan countries.
    Drulovic J; Cukic M; Grgic S; Dincic E; Raicevic R; Nadj C; Toncev G; Vojinovic S; Mesaros S; Kisic Tepavcevic D; Dujmovic I; Tadic D; Miletic-Drakulic S; Dackovic J; Kostic S; Erakovic J; Sakalas L; Savic D; Suknjaja V; Martinovic V; Maric G; Pekmezovic T
    Mult Scler Relat Disord; 2017 Jan; 11():56-61. PubMed ID: 28104258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis.
    Mokhber N; Azarpazhooh A; Orouji E; Khorram B; Modares Gharavi M; Kakhi S; Khallaghi H; Azarpazhooh MR
    Psychiatry Clin Neurosci; 2015 Oct; 69(10):649-57. PubMed ID: 25907350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
    Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations.
    Evans C; Marrie RA; Zhu F; Leung S; Lu X; Kingwell E; Zhao Y; Tremlett H
    Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):702-711. PubMed ID: 28370875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy).
    Moccia M; Loperto I; Lanzillo R; Capacchione A; Carotenuto A; Triassi M; Brescia Morra V; Palladino R
    BMC Health Serv Res; 2020 Aug; 20(1):797. PubMed ID: 32847587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study.
    Steinberg SC; Faris RJ; Chang CF; Chan A; Tankersley MA
    Clin Drug Investig; 2010; 30(2):89-100. PubMed ID: 20067327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study.
    Kleiter I; Lang M; Jeske J; Norenberg C; Stollfuß B; Schürks M
    BMC Neurol; 2017 Sep; 17(1):174. PubMed ID: 28877664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.
    Hoffmann FA; Trenova A; Llaneza MA; Fischer J; Lus G; von Bredow D; Lara N; Lam E; Van Hoef M; Bakshi R
    BMC Neurol; 2017 Aug; 17(1):156. PubMed ID: 28793876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The results of longitudinal use of copaxone and betaferon in Moscow Multiple Sclerosis Center: issues of efficacy and adherence to therapy].
    Boĭko AN; Davydovskaia MF; Demina TL; Lashch NIu; Ovcharov VV; Popova NF; Sinbukhova NI; Khachanova NV; Shchur SG; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():101-10. PubMed ID: 17172244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.